Tho Lai

Genetic alterations in SUPT6H are associated with neurodevelopmental disorders

Bruno Carabelli, H. Kim, Bonsu Ku, Clara Berdasco et autres

Genetic variants affecting the RNA polymerase II complex have been associated with various neurodevelopmental disorders (NDDs). SUPT6H, an RNA polymerase II-associated elongation factor and a histone chaperone, plays a critical role in transcriptional regulation. However, the contribution of SUPT6H variants to human …

us, kr (code pays fourni par la source)

Figure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski, Si-Qi Liu, Lauren M. Zasadil, Joseph L. Benci et autres

Fig. S3. Antigen specific T cell response in the CT26 model.

Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski, Si-Qi Liu, Lauren M. Zasadil, Joseph L. Benci et autres

Table S2

Figure S6 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski, Si-Qi Liu, Lauren M. Zasadil, Joseph L. Benci et autres

Fig. S6. Additional NSCLC PDOT data.

Figure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski, Si-Qi Liu, Lauren M. Zasadil, Joseph L. Benci et autres

Fig. S1. BMS-986408 DGK family selectivity and activity and in T cell functional assays.

Figure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski, Si-Qi Liu, Lauren M. Zasadil, Joseph L. Benci et autres

Fig. S7. Additional BMS-986408/CAR-T combination data.

Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski, Si-Qi Liu, Lauren M. Zasadil, Joseph L. Benci et autres

Table S4

Table S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski, Si-Qi Liu, Lauren M. Zasadil, Joseph L. Benci et autres

Table S3

Figure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski, Si-Qi Liu, Lauren M. Zasadil, Joseph L. Benci et autres

Fig. S2. Additional BMS-986408 mechanism of action data.

Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski, Si-Qi Liu, Lauren M. Zasadil, Joseph L. Benci et autres

Table S5

Figure S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski, Si-Qi Liu, Lauren M. Zasadil, Joseph L. Benci et autres

Fig. S4. Mono-selective DGKα and DGKζ inhibitor characterization.

Table S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski, Si-Qi Liu, Lauren M. Zasadil, Joseph L. Benci et autres

Table S1